BS_X4X1SFSE
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 12.319316688567673
- age_years
- 7.31
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.328
- E2F_TARGETS+0.325
- PROTEIN_SECRETION+0.310
- OXIDATIVE_PHOSPHORYLATION+0.299
- MTORC1_SIGNALING+0.294
- G2M_CHECKPOINT+0.283
- NOTCH_SIGNALING+0.230
- MYC_TARGETS_V1+0.216
- MITOTIC_SPINDLE+0.208
- BILE_ACID_METABOLISM+0.173
Top 10 suppressed
- ANGIOGENESIS-0.396
- TNFA_SIGNALING_VIA_NFKB-0.351
- APICAL_SURFACE-0.347
- IL6_JAK_STAT3_SIGNALING-0.328
- COAGULATION-0.309
- MYC_TARGETS_V2-0.309
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.303
- WNT_BETA_CATENIN_SIGNALING-0.284
- INFLAMMATORY_RESPONSE-0.265
- APICAL_JUNCTION-0.257
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R391 | — | — | 0.844 |
| 2 | BS_5965SFPZ | Diffuse intrinsic pontine glioma | — | 0.839 |
| 3 | R288 | — | — | 0.826 |
| 4 | R150 | — | — | 0.813 |
| 5 | SRR12202430 | — | — | 0.806 |
| 6 | MNG641 | — | — | 0.790 |
| 7 | DRR168591 | — | — | 0.782 |
| 8 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.771 |
| 9 | R137 | — | — | 0.764 |
| 10 | 48507_S107 | — | cohortMD1 | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.328 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.325 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.299 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.294 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.283 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.216 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.208 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.173 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.164 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.138 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.123 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.109 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.099 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.093 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.081 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.068 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.027 | Inavolisib | — uncovered |